Latest Content

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation.

CRS and ICANS were observed in 48% and 16%, respectively, of patients with ES-SCLC who received tarlatamab, according to real-world data.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

In the phase 3 SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide as second-line therapy for high-risk essential thrombocythemia.

Cassie A. Gray, MS, RN, OCN, CHPN, explains how early palliative care integration benefits patients with advanced cancer.

Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, shared a review of supportive oncology practices at the 2025 School of Nursing Oncology.

The FDA has approved lurbinectedin plus atezolizumab for the treatment of extensive-stage small cell lung cancer following induction therapy with atezolizumab.

The addition of atezolizumab to chemoradiation led to meaningful improvements to quality of life for patients with small cell lung cancer.

Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, explains the utility of a holistic approach to oncology care.

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.